Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price isCNY 18...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion
SHANGHAI, July 11, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totalingUS$3.2 billion, including USD Fund VIII atUS$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million). As in prior funds, Fund VIII was oversub...
Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates
Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 11, 2022 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced...
Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List
SHANGHAI, April 13, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, andDuane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list. Since ...
Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX
SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. In this secondary listing, the issue price is HK$5...
Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates
SHANGHAI and SAN FRANCISCO, Aug. 13, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced financial results for the six months ended June 30, 2020 and corporate updates. "This year we have continued to build Zai Lab's lead...
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
SHANGHAI and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib...
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China
SHANGHAI, July 8, 2020 /PRNewswire/ -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced an...
Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
SHANGHAI and SAN FRANCISCO, May 29, 2020 /PRNewswire/ -- Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced positive topline results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (n...
Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam- Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
SHANGHAI and SAN FRANCISCO, May 19, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial...
Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates
SHANGHAI and SAN FRANCISCO, March 19, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), aChina and U.S.-based innovative commercial stage biopharmaceutical company, today announced financial results for the twelve months endedDecember 31, 2019 and corporate updates. "Coinciding with the celeb...
